Skip to main content
SpringerLink
Log in

Comment on: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”

  • Letter to the Editor
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Scheen AJ. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014;53:773–85.

    Article  CAS  PubMed  Google Scholar 

  2. Barbehenn E, Almashat S, Carome M, Wolfe S. Hepatotoxicity of alogliptin. Clin Pharmacokinet. 2014;53:1055–6.

    Article  PubMed  Google Scholar 

  3. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, EXAMINE Investigators, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.

    Article  CAS  PubMed  Google Scholar 

  4. Scheen AJ. Alogliptin: concern about hepatotoxicity? Clin Pharmacokinet. 2014;53:1057–9.

    Article  PubMed  Google Scholar 

  5. Brinker AD, Lyndly J, Tonning J, Moeny D, Levine JG, Avigan MI. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database. Drug Saf. 2013;36:1169–78.

    Article  CAS  PubMed  Google Scholar 

  6. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34:1369–71.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (AERS). In: Karahoca A, editor. Data mining applications in engineering and medicine. Croatia: InTech; 2012. p. 267–301.

    Google Scholar 

  8. Raschi E, Poluzzi E, Koci A, Caraceni P, De Ponti F. Assessing liver injury associated with antimycotics: concise literature review and clues from data mining of the FAERS database. World J Hepatol. 2014;6:601–12.

    PubMed Central  PubMed  Google Scholar 

  9. Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010;33:503–22.

    Article  CAS  PubMed  Google Scholar 

  10. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51:501–14.

    Article  CAS  PubMed  Google Scholar 

  11. US Food and Drug Administration. Product Information: sitagliptin. 2013. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021995s028lbl.pdf. Accessed 3 Dec 2014.

  12. European Medicines Agency. Summary of product characteristics: sitagliptin. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000722/WC500039054.pdf . Accessed 3 Dec 2014.

Download references

Acknowledgments

The original research of the authors is funded by institutional Grants from the University of Bologna. The authors would like to thank Ariola Koci (Research Fellow in Statistics) and Ippazio Cosimo Antonazzo (MSc), Department of Medical and Surgical Sciences, University of Bologna, for assistance in data extraction and management of the FAERS database.

Conflicts of interest

Emanuel Raschi, Elisabetta Poluzzi and Fabrizio De Ponti declare no conflicts of interest that are relevant to the content and preparation of this letter.

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Via Irnerio, 48, 40126, Bologna, Italy

    Emanuel Raschi, Elisabetta Poluzzi & Fabrizio De Ponti

Authors
  1. Emanuel Raschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabetta Poluzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fabrizio De Ponti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabrizio De Ponti.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Raschi, E., Poluzzi, E. & De Ponti, F. Comment on: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”. Clin Pharmacokinet 54, 447–448 (2015). https://doi.org/10.1007/s40262-015-0248-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-015-0248-4

Keywords

Search

Navigation